Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 12,520 matching trials from the live ClinicalTrials.gov search.
Filters: Miami, Florida Clear all
Completed Phase 2 Interventional

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

NCT01398423
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Active Control, INV-144
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Garden Grove, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting No phase listed Observational

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

NCT03687359
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Standard of care
Other
Lead sponsor
Sanofi
Industry
Eligibility
0 Years to 11 Years
Enrollment
1,860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
46
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Phase 2 Interventional

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

NCT05554380
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Phase 3 Interventional

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT04786262
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Interventions
VX-880, VX-017
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Terminated Phase 3 Interventional Results available

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

NCT04218084
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 14 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Not applicable Interventional

Effectiveness and Safety of Embosphere Microspheres for Embolization of the Geniculate Artery for the Treatment of Pain With Known Moderate to Severe Knee Osteoarthritis

NCT05112926
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Embosphere Microspheres
Device
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Phase 3 Interventional

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835
View directory record Official record
Conditions
Chronic Kidney Disease With High Proteinuria
Interventions
Zibotentan/Dapagliflozin, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
64
States / cities
Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 1 Interventional

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

NCT03649971
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
44
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
51
States / cities
Birmingham, Alabama • Lafayette, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

NCT00876798
View directory record Official record
Conditions
Euvolemic Hyponatremia
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
66
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Nov 5, 2026, 4:23 AM EST
Completed No phase listed Observational

Association Between Cancer and Sarcoidosis

NCT03844698
View directory record Official record
Conditions
Sarcoidosis, Cancer
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Nov 5, 2026, 4:23 AM EST
Completed No phase listed Observational

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

NCT02636855
View directory record Official record
Conditions
Solid and Hematological Malignancies
Interventions
Not listed
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years to 75 Years
Enrollment
9,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
25
States / cities
Duarte, California • Stanford, California • Boca Raton, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ORIC-101 in Healthy Adult Subjects

NCT03324555
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ORIC-101
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

NCT03354598
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infections
Interventions
Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tolleson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Nov 5, 2026, 4:23 AM EST
Completed No phase listed Observational

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

NCT01302587
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
25
States / cities
Glendale, Arizona • Mission Viejo, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Nov 5, 2026, 4:23 AM EST
Not listed Phase 2Phase 3 Interventional Results available

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

NCT02065687
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
431
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Nov 5, 2026, 4:23 AM EST
Completed No phase listed Observational

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

NCT00256633
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Nov 5, 2026, 4:23 AM EST
Completed Not applicable Interventional Results available

PRimary Care Opioid Use Disorders Treatment (PROUD) Trial

NCT03407638
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
PROUD Intervention
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
16 Years to 90 Years
Enrollment
377,373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Miami, Florida • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Terminated Phase 2 Interventional

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT03245385
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Treatment with Halobetasol propionate 0.05% topical spray
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

NCT02847598
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Interventions
BIIB059 (litifilimab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
53
States / cities
Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 2 Interventional

A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection

NCT00000716
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 5, 2026, 4:23 AM EST